What are the differences between metoprolol tartrate (immediate‑release) and metoprolol succinate (extended‑release), including dosing regimens, clinical indications, and conversion between them?

Metoprolol Tartrate vs. Metoprolol Succinate: Key Differences

Metoprolol succinate (extended-release) is the preferred formulation for heart failure with reduced ejection fraction, while metoprolol tartrate (immediate-release) is appropriate for acute settings and conditions requiring flexible dosing such as hypertension and acute coronary syndromes.

Formulation and Pharmacokinetics

Metoprolol Tartrate (Immediate-Release)

• Dosing frequency: 2-4 times daily due to shorter half-life (3-7 hours) 1
• Pharmacokinetics: Produces marked peak and trough plasma concentrations with significant fluctuation throughout the dosing interval 1
• Peak effect: Larger initial peak effect on heart rate but effect not sustained at 24 hours when dosed once or twice daily 1
• Bioavailability: ~50% due to first-pass metabolism 1

Metoprolol Succinate (Extended-Release/CR)

• Dosing frequency: Once daily 1
• Pharmacokinetics: Near-constant (zero-order) drug release over 20-24 hours, producing stable plasma concentrations without marked peaks and troughs 1, 2
• Beta-blockade: Maintains relatively constant beta1-blockade throughout entire 24-hour dosing interval 1
• Bioavailability: Similar first-pass metabolism but more efficient utilization of plasma concentrations due to sustained release 3

Clinical Indications

Heart Failure with Reduced Ejection Fraction (HFrEF)

Metoprolol succinate is the ONLY metoprolol formulation proven to reduce mortality in heart failure. 4, 5

• Evidence-based dosing for HFrEF:

  • Starting dose: 12.5-25 mg once daily
  • Target dose: 200 mg once daily
  • Titration: Double dose every 1-2 weeks as tolerated 4

• Critical distinction: The MERIT-HF trial, which demonstrated 34% reduction in all-cause mortality, used metoprolol succinate CR/XL 200 mg daily 6. Metoprolol tartrate has NOT shown equivalent mortality benefits in prospective trials 7.

• Comparative data: In the COMET trial, metoprolol tartrate immediate-release was inferior to carvedilol for mortality reduction in heart failure 7. This underscores that the formulation matters significantly for outcomes.

Hypertension

Both formulations are effective, but dosing differs:

• Metoprolol tartrate: 100-200 mg daily in divided doses (typically twice daily) 8
• Metoprolol succinate: 25-100 mg once daily for hypertension; 50-200 mg once daily for more comprehensive cardiovascular protection 8, 1

Important caveat: The target dose for hypertension (25-100 mg daily) is LOWER than the target dose proven effective in heart failure (200 mg daily) 9. Many physicians incorrectly assume hypertension doses are adequate for heart failure—they are not.

Acute Coronary Syndromes and Angina

Metoprolol tartrate is preferred in acute settings due to:

• Ability to titrate rapidly with IV formulation (5 mg IV every 5 minutes up to 3 doses) 10
• Transition to oral: 25-50 mg every 6-12 hours initially, then convert to twice-daily or once-daily succinate formulation 10
• Flexibility for dose adjustments in unstable patients

Atrial Fibrillation (Rate Control)

Both formulations effective for chronic rate control:

• Acute setting: Metoprolol tartrate 2.5-5 mg IV bolus over 2 minutes, up to 3 doses 11
• Chronic maintenance: Metoprolol tartrate 25-100 mg twice daily OR metoprolol succinate equivalent once-daily dose 11

Conversion Between Formulations

The conversion is NOT 1:1 in terms of clinical effect, despite similar total daily beta-blockade at equivalent doses.

Pharmacokinetic Equivalence

• 100-400 mg total daily dose of either formulation produces comparable total beta1-blockade over 24 hours (area under the curve) 1
• However, at 50 mg daily, metoprolol succinate produces significantly higher total beta1-blockade than tartrate 1

Practical Conversion Strategy

When converting from tartrate to succinate:

1. Calculate total daily tartrate dose
2. Use same total daily dose of succinate given once daily
3. Critical exception: For heart failure patients, the TARGET is 200 mg succinate daily regardless of prior tartrate dose 4

Example conversions:

• Metoprolol tartrate 50 mg twice daily (100 mg total) → Metoprolol succinate 100 mg once daily
• Metoprolol tartrate 25 mg three times daily (75 mg total) → Metoprolol succinate 100 mg once daily (round up for heart failure)

Hemodynamic Considerations

Important finding: Both formulations produce similar acute hemodynamic effects when readministered during chronic therapy, including decreases in cardiac index and increases in systemic vascular resistance 12. The succinate formulation does NOT avoid these acute effects but distributes them more evenly over 24 hours.

Dosing Regimens by Indication

Heart Failure (HFrEF) - Metoprolol Succinate ONLY

• Initial: 12.5-25 mg once daily 4, 5
• Titration: Increase by doubling dose every 1-2 weeks 4
• Target: 200 mg once daily 4, 5
• Mean achieved in trials: 159 mg daily 5

Hypertension

• Tartrate: 25-100 mg twice daily 8
• Succinate: 25-100 mg once daily (up to 200 mg for comprehensive effect) 8

Post-Myocardial Infarction

• Acute (tartrate): 25-50 mg every 6-12 hours, then transition 10
• Chronic (succinate): Titrate to 200 mg once daily for maximal mortality benefit 10

Common Pitfalls to Avoid

1. Using metoprolol tartrate for heart failure: Only succinate has proven mortality benefit 4, 6, 7

2. Underdosing in heart failure: The target dose is 200 mg daily of succinate, NOT the 25-100 mg used for hypertension 9. Physicians often stop at "medium" doses incorrectly believing they provide most benefits—they do not 9.

3. Assuming formulations are interchangeable: While total beta-blockade may be similar, the temporal distribution differs significantly, affecting both efficacy and tolerability 1

4. Permanent dose reductions: In clinical trials, 40% of patients requiring temporary dose reduction were successfully restored to target doses 9. In practice, dose reductions are often permanent—this should be avoided.

5. Confusing FDA-approved doses with evidence-based doses: The dose of metoprolol for hypertension/angina (25-100 mg) is far lower than the target dose proven effective in heart failure trials (200 mg) 9

Tolerability and Titration

Both formulations require careful titration, but succinate offers advantages:

• More stable heart rate control over 24 hours 1
• Maintained cardioselectivity at doses up to 200 mg daily 2
• More consistent beta1-blockade at trough (24 hours post-dose) 1

Monitoring during titration (applies to both):

• Heart rate, blood pressure, signs of fluid retention 4
• If hypotension: reduce vasodilators first, then beta-blocker if necessary 4
• If worsening heart failure: increase diuretics/ACE inhibitors first 4
• Always attempt reintroduction and uptitration when patient stabilizes 4

4, 8, 11, 10, 5, 6, 1, 7, 12, 2